My colleague Dr. Aqeel Gillani shared with me his presentation on Interstitial Lung Diseases today. He had to speak on this topic during one of the routine discussions.
Interstitial Lung Diseases are a heterogeneous group of disorders characterized by inflammation and/or fibrosis of the pulmonary interstitium leading to impaired oxygen transfer and ultimately scarring within the lung. It is essential to note that the parenchyma is the primary site of injury in these diseases.
In 2002, the American Thoracic Society (ATS) and European Respiratory Society (ERS) revised the original
classification scheme and introduced the term diffuse parenchymal lung disease (DPLD) in place of the term ILD.
The guidelines classify these disorders into 4 categories:
(1) DPLDs of known association (eg, drugs, connective tissue diseases, and environmental/occupational exposures),
(2) Granulomatous DPLDs (eg, sarcoidosis),
(3) Other and often rare DPLDs (eg, lymphangioleiomyomatosis, pulmonary Langerhans cell histiocytosis, pulmonary alveolar proteinosis, and eosinophilic pneumonia).
(4) The idiopathic interstitial pneumonias (IIPs). The IIPs are further subdivided into usual interstitial pneumonia [UIP; with its clinical counterpart idiopathic pulmonary fibrosis (IPF) when no known cause is identified for the UIP pattern], nonspecific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia,acute interstitial pneumonia, desquamative interstitial pneumonia, respiratory bronchiolitis ILD,and lymphocytic interstitial pneumonia.
The definition of IPF requires the exclusion of other forms of interstitial pneumonia including other idiopathic interstitial pneumonias and ILD associated with environmental exposure, medication, or systemic disease.
I think I will share the presentation now instead of continuing with the usual lecture. I do hope you like the presentation.